Amgen logo

AmgenAMGN

NASDAQ

Biotech

$438.50-0.06%

AI Multi-Horizon Analysis

Short-term45% confidence
Neutral

No intraday technical levels or momentum indicators supplied; price action likely to reflect broader positive fundamental backdrop but remains range-bound absent new catalyst.

Mid-term60% confidence
Bullish

Q3 earnings/FCF surge and margin expansion likely to support near-term price action; any pullback viewed as buying opportunity given cash-flow strength.

Long-term65% confidence
Bullish

Multi-quarter revenue acceleration, expanding margins, record FCF, deleveraging, and equity-base growth provide strong foundation for continued outperformance if pipeline executes.

Overall AI View65% confidence
Bullish

Strong accelerating revenue, margins, net income, and FCF; materially improved balance sheet with declining leverage and growing equity. Fundamentals clearly positive with neutral insider tone.

Detailed AI Fundamental Analysis

Business Snapshot

AMGN is a long-established biotechnology company (listed 1983) focused on the discovery, development, and commercialization of human therapeutics, primarily in the category of biological products. With a market capitalization of approximately $249 billion and roughly 31,500 employees, the firm maintains a substantial global presence. Its product portfolio targets serious illnesses including oncology, inflammation, bone health, and cardiovascular disease. The company generates robust cash flow from a mature set of blockbuster drugs while continuing to invest in R&D and selective acquisitions to replenish its pipeline.

Financial Trends

Revenue has shown clear acceleration across the reported quarters. Quarterly revenue rose from $8.618 billion in Q1 2026 to $10.054 billion in Q2 2026 (+16.7% Q2 vs Q1) and further to $10.365 billion in Q3 2026 (+3.1% Q3 vs Q2). On a trailing basis, the latest three quarters total $29.037 billion compared with the full-year 2025 revenue of $36.751 billion, indicating a strong run-rate.

Operating and net margins have expanded materially. Operating margin improved from 30.94% in Q1 to 34.95% in Q2 and 35.79% in Q3 (latest +4.85 percentage points vs Q1). Net margin expanded even more dramatically from 21.11% in Q1 to 23.62% in Q2 and 37.28% in Q3, driven largely by a Q3 net income spike to $3.864 billion versus $2.375 billion in Q2 (+62.7% Q3 vs Q2) and $1.819 billion in Q1. EPS (diluted) followed suit: $3.34 in Q1, $4.37 in Q2, and $7.08 in Q3.

Free cash flow trajectory is strongly positive and accelerating. FCF rose from $1.477 billion in Q1 to $4.966 billion in Q2 (+236% Q2 vs Q1) and reached $8.620 billion in Q3 (+73.6% Q3 vs Q2). The latest quarter’s FCF alone exceeds the full-year 2025 FCF of $8.100 billion, underscoring accelerating cash generation.

Balance-sheet strength has improved markedly. Total assets grew steadily from $90.586 billion at end-2025 to $96.048 billion at end-Q3 2026 (+6.0% latest vs four periods ago). Shareholders’ equity expanded aggressively from $8.658 billion to $14.352 billion (+65.8% latest vs four periods ago), aided by retained earnings recovering from –$25.107 billion to –$19.807 billion. Current ratio climbed from 1.14 to 1.48, while debt/equity fell from 5.78 to 3.60, reflecting deleveraging and a healthier capital structure. Cash & equivalents rose from $9.129 billion to $13.190 billion despite elevated capital expenditures and financing outflows.

Financial Health

The latest Q3 2026 results reflect a company in excellent and improving financial health. Record quarterly revenue, sharply higher margins, and outsized net income produced FCF of $8.62 billion—more than the entire prior full year—while the balance sheet continued to strengthen. Liquidity is solid (current ratio 1.48, working capital $11.13 billion), long-term debt is stable around $51.6 billion, and the equity base has grown rapidly. The negative retained earnings position is shrinking quickly, and overall leverage (debt/equity 3.60) has declined meaningfully. Cash generation now comfortably funds capex, dividends, and debt service, positioning AMGN with increasing flexibility for pipeline investment, share repurchases, or further deleveraging.

Insider Activity

Insider sentiment over the most recent reporting window (August–November 2026) is Neutral with a modest net sell bias of –$1.14 million. There were two buy transactions totaling $0.20 million and three sell transactions totaling $1.35 million. No Form 4 or Form 5 filings were recorded in the October–November 2026 window itself. The small net selling is not aggressive relative to AMGN’s market capitalization and may reflect routine tax withholding or diversification rather than a negative view of fundamentals.

Multi-Timeframe Technical Context

On the ultra-short (minute) timeframe the current price of $464.61 sits within a regular trading session with no immediate session high/low extremes provided. Short-term (hourly to daily) price action would be viewed in the context of the strong fundamental momentum; any near-term pullback would likely be supported by robust cash-flow trends and improving balance-sheet metrics. On the long-term (weekly to monthly) horizon, AMGN’s sustained revenue acceleration, margin expansion, and equity growth suggest underlying accumulation, though the elevated absolute valuation typical of large-cap biotech requires continued earnings delivery to sustain multiple support. No specific moving-average, RSI, or volume indicator values were supplied in the current data set.

Bull / Bear Cases

Short-term Bull: Continued momentum from Q3’s outsized earnings and FCF beat drives sentiment higher; any positive pipeline update or guidance raise could catalyze a quick move above $464.61 as traders price in further margin gains and cash deployment.

Short-term Bear: Profit-taking after the strong Q3 net-income surge or broader sector rotation out of biotech could pressure the stock toward near-term support; absence of new insider buying reinforces a neutral tactical stance.

Long-term Bull: Sustained revenue and margin expansion, rapidly improving equity base, declining leverage, and accelerating FCF provide a solid foundation for multiple re-rating. Successful pipeline assets or strategic deployment of the $13.2 billion cash balance could compound shareholder value over weeks-to-months.

Long-term Bear: If new product launches fail to offset any future patent expirations, or if R&D spending rises faster than expected, the current margin trajectory could plateau. Persistent negative retained earnings (even if shrinking) and a still-elevated debt load remain structural reminders that execution risk exists.

Key Levels & Triggers

  • Immediate resistance: Any move above $464.61 that holds on increased volume would target prior session highs (not supplied); clear break could open further upside.
  • Near-term support: Watch the rising trend of working capital and equity growth for fundamental support around recent quarterly lows.
  • Positive triggers: Beat-and-raise earnings, accelerated share repurchases funded by $8.6 billion quarterly FCF, or further debt/equity reduction below 3.60.
  • Negative triggers: Margin contraction, unexpected increase in long-term debt, or renewed net insider selling on larger scale.
  • Key metric to monitor: Quarterly FCF relative to capex and dividends; sustained FCF above $5 billion per quarter would reinforce both short- and long-term bullish theses.

Financials

From SEC EDGAR · Period 2026-09-30 · Source form 10-Q

Income Statement · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-K
Revenue$10.37B$10.05B$8.62B$36.75B
Operating Income$3.71B$3.51B$2.67B$9.08B
Net Income$3.86B$2.38B$1.82B$7.71B
EPS (Diluted)$7.08$4.37$3.34$14.23
Operating Margin35.79%34.95%30.94%24.71%
Net Margin37.28%23.62%21.11%20.98%

Balance Sheet · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-Q
Total Assets$96.05B$95.64B$92.50B$90.59B
Shareholders' Equity$14.35B$11.69B$9.19B$8.66B
Cash & Equivalents$13.19B$13.99B$12.04B$9.13B
Long-term Debt$51.61B$51.86B$51.89B$50.01B
Current Ratio1.481.371.261.14
Debt / Equity3.604.445.655.78

Cash Flow · last 4 periods

 
2026-09-30
10-Q
2026-06-30
10-Q
2026-03-31
10-Q
2025-12-31
10-K
Cash from Operations$10.43B$6.19B$2.19B$9.96B
Cash from Investing-$1.93B-$1.28B-$716.00M-$1.94B
Cash from Financing-$4.44B-$46.00M$1.44B-$10.86B
Capital Expenditures$1.81B$1.23B$712.00M$1.86B
Free Cash Flow$8.62B$4.97B$1.48B$8.10B

Income Statement

Revenue
$29.04B
Gross Profit
$4.74B
Operating Income
$9.89B
Net Income
$8.06B
EPS (Basic)
$14.92
EPS (Diluted)
$14.79

Balance Sheet

Total Assets
$96.05B
Total Liabilities
—
Shareholders' Equity
$14.35B
Cash & Equivalents
$13.19B
Long-term Debt
$51.61B
Shares Outstanding
540.91M

Cash Flow

Cash from Operations
$10.43B
Cash from Investing
-$1.93B
Cash from Financing
-$4.44B
Capital Expenditures
$1.81B
Free Cash Flow
$8.62B

Key Ratios

Gross Margin
16.31%
Operating Margin
34.06%
Net Margin
27.75%
Current Ratio
1.48
Debt / Equity
3.60
Free Cash Flow
$8.62B

Key Stats

$235.52BMarket cap
$391.2952-week high
$261.4352-week low
2,643,409Avg volume (30d)

31,500 employees540.63M shares outstandinglisted 1983-06-17dividend yield 2.98%

Next earnings ~May 5, 2026 · Ex-dividend May 15, 2026 · Dividend $2.52 quarterly

About Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Latest News

Showing market-wide stock news

AMGN catalysts

We track AMGN on Sector Watch from primary sources. See its FDA dates, trials and filings

Related Stocksin Biotech

Related research

More in Market history

Ready to see the live AI view on AMGN?

Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing AMGN side-by-side with live signals.